United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that shareholders and the general public are invited to access its virtual-only 2021 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 22, 2021. As previously disclosed, this year's meeting will be held virtually due to continued public health concerns related to the COVID-19 pandemic and to support the health and well-being of our shareholders and other meeting participants. We have designed the virtual Annual

Pfizer Invites Shareholders to Attend Virtual-Only 2021 Annual Meeting of Shareholders on April 22

BioNTech SE

Pfizer CEO Albert Bourla said earlier this month that people will likely require booster shots within 12 months of getting fully vaccinated — as early as December for some. "It is extremely important to suppress the pool of people that can be susceptible to the virus," Bourla told CNBC's Bertha Coombs on April 1.

People will likely need a booster shot of Pfizer's vaccine within 12 months, Pfizer's CEO said

Pfizer CEO Albert Bourla said people will “likely” need a third dose of a Covid-19 vaccine within 12 months of getting fully vaccinated.

Pfizer CEO says third Covid vaccine dose likely needed within 12 months

AstraZeneca

Moderna

The study has major implications given how regulators have reacted to blood-clot concerns.

Pfizer and Moderna Vaccines About as Likely to Trigger Blood Clots as AstraZeneca's, Study Finds

A study by Oxford University found the number of people who receive blood clots after getting vaccinated with a coronavirus vaccine are about the same for those who get Pfizer and Moderna vaccines as they are for the AstraZeneca vaccine that was produced with the university's help. According to CBS News, based on a preprint study, 4 in 1 million people experience cerebral venous thrombosis after getting the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine.

Blood clots as prevalent with Pfizer and Moderna vaccine as with AstraZeneca's: report

Could This Cheap COVID Vaccine Spell Doom for Pfizer and Moderna?

Jeff Zients said the FDA's recommended pause on J&J's vaccine would not have a "significant impact" on the administration's vaccination program.

White House says U.S. is working to accelerate doses of Pfizer, Moderna Covid vaccines

PFE stock is cheap, and a 4.2% dividend yield looks attractive. But that case has failed for years now; without growth, nothing will change.

Investors Can Do Better Than Low-Growth Pfizer Stock

The pharmaceutical's CEO tweeted that an extra 20 million doses will arrive by the end of May.

Pfizer Will Deliver More Covid-19 Shots. The Word Comes After J&J's Version Is Pulled.

AbbVie

Worried about sky-high valuations? Check out these two pharma stocks.

Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now

Johnson & Johnson

A comparison between COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX), Moderna's (MRNA), AstraZeneca (AZN) and J&J (JNJ) is inevitable.

Which Vaccine Maker Will Win the Fight Against COVID-19?

The European Union has reached an agreement to speed up delivery of 50 million more doses of the BioNTech-Pfizer COVID-19 vaccines to boost the continent's vaccination program. "Those 50 million doses were initially foreseen for delivery in the fourth quarter of 2021.

EU moves up delivery for 50 million BioNTech and Pfizer COVID-19 doses

Kimberly-Clark

AT&T

The ability to pay a regular, rising dividend is a signal of past business success and future reliability.

You Can Make $250 Every Month From Investing in These 3 Stocks

Millions of kids could soon be allowed to receive Pfizer's COVID-19 vaccine. Will the big drugmaker make some big bucks this year?

Here's the Surprising Amount of Money Pfizer's Vaccine Might Make Immunizing Adolescents

Myovant Sciences

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study

The announcement comes as the CDC and FDA recommended a pause on administering Johnson & Johnson's vaccine.

Pfizer Says It Can Deliver 10% More Doses In May Than Previously Promised

Pfizer has increased its production of COVID-19 vaccines and will deliver remaining doses to the United States faster than expected, the company's CEO Albert Bourla said on Twitter. Bourla said his company will deliver 220 million doses of the vaccine by the end of May — 10% more than previously agreed on.

Pfizer is ramping up vaccine production and will meet its goal of 300 million doses two weeks early, its CEO said

Pfizer Inc. Chief Executive Albert Bourla tweeted late Tuesday that the pharma company has "ramped up" production of its COVID-19 vaccine, and will be able to deliver 10% more doses to the U.S. by the end of May than a previously agreed total of 220 million doses, as well as supply "the full (300 million doses) agreed on for the end of July two weeks early." "In the fight against COVID-19, we're in this together," the CEO said.

Pfizer ramps up COVID-19 vaccine production for the U.S., CEO says

CEO Albert Bourla said Pfizer can deliver 10% more doses to the U.S. by the end of May than it had previously agreed to produce.

Pfizer CEO says company can deliver 10% more doses to the U.S. by the end of May than previously agreed

Novavax

Johnson & Johnson's (NYSE: JNJ) pain has proved to be gain for other vaccine companies, including BioNTech SE (NASDAQ: BNTX), Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA) and Novavax, Inc. (NASDAQ: NVAX). What Happened: The Food and Drug Administration and the Centers for Disease Control and Prevention announced it's recommending pausing of the use of J&J's single-shot coronavirus vaccine, attributing the decision on incidents of severe, atypical blood clots.

Why Vaccine Stocks Pfizer, BioNTech, Moderna And Novavax Are Higher

Investors viewed bad news for Johnson and Johnson's COVID-19 vaccine as good news for Moderna and Pfizer on Tuesday, which both climbed after the CDC called for a pause in the use of J&J's single-dose COVID-19 vaccine. Shares of Moderna surged as much as 7%, while Pfizer and its COVID vaccine partner BioNTech jumped 1% and 3% in Tuesday trades, respectively. Shares of J&J dropped as much as 3% before paring a portion of those losses.

Moderna and Pfizer shares climb after CDC calls for pause in use of J&J COVID-19 vaccine

It can already claim it contributed to both companies' COVID vaccines.

News for Pfizer Stock (PFE)